ContractSecurities Purchase Agreement • March 10th, 2015 • Tapimmune Inc • Pharmaceutical preparations • New York
TAPIMMUNE INC. WARRANT TO PURCHASE COMMON STOCKPlacement Agent Series a-1 Warrant • March 10th, 2015 • Tapimmune Inc • Pharmaceutical preparations • New York
TapImmune Inc., a Nevada corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [--------------], the registered holder hereof or its permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”), at any time or times on or after the Issuance Date but not after 11:59 p.m., New York time, on the Expiration Date (as defined below), [-----] (subject to adjustment as provided herein) fully paid and non-assessable shares of Common Stock (as defined below) (the “Warrant Shares”). Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth in Section 16. This Warrant is one of th
March 9, 2015 STRICTLY CONFIDENTIAL Glynn Wilson, Ph.DChairman & CEO TapImmune, Inc.1551 Eastlake Avenue East, Suite 100Seattle, WA 98102 Dear Dr. Wilson:Engagement Letter • March 10th, 2015 • Tapimmune Inc • Pharmaceutical preparations
Reference is made to the exclusive engagement letter (the “Engagement Letter”), dated July 29, 2014, as amended January 10, 2015, by and between TapImmune Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright shall serve as the exclusive investment bank of the Company during the “Term” (as defined in the Engagement Letter).
